Results 161 to 170 of about 467,605 (318)
Influence of the Novel Histamine H3 Receptor Antagonist/Inverse Agonist M39 on Gastroprotection and PGE2 Production Induced by (R)-Alpha-Methylhistamine in C57BL/6 Mice [PDF]
, 2019 Salim M. A. Bastaki +4 more
openalex +1 more source
Should the non‐canonical pathway of nitric oxide generation be targeted in hypertensive pregnancies?
British Journal of Pharmacology, Volume 183, Issue 1, Page 57-69, January 2026.Abstract Hypertension in pregnancy is prevalent, affecting around 10% of pregnancies worldwide, and significantly increases the risk of adverse outcomes for both mothers and their babies. Current treatment strategies for pregnant women with hypertension are limited, and new approaches for the management of hypertension in pregnancy are urgently needed.
Elizabeth C. Cottrell
wiley +1 more source
Community Pharmacy‐Based Injectable Opioid Agonist Treatment: Findings From a Canadian Pilot Program
Drug and Alcohol Review, Volume 45, Issue 1, January 2026.ABSTRACT Introduction Access to evidence‐based treatment for opioid use disorder remains limited, particularly for individuals who have not responded to oral opioid agonist treatment (OAT). A community pharmacy‐based model of injectable OAT (iOAT) was piloted in Vancouver, Canada from March 2017 to December 2018. This brief report describes the program
Tamara Mihic +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 316-323, January 2026.Abstract Aims While discontinuation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) before esophagogastroduodenoscopy (EGD) is not universally mandated, safety concerns persist. Evidence remains insufficient for managing specific patient subgroups, particularly in Asian populations. We aimed to provide evidence for stratified risk assessment in
Hiroyuki Hisada +13 more
wiley +1 more source